Amplifon shares jumped 7.7% to close at c12.09 after the Italian hearing care specialist published stronger-than-expected Q2 and H1 2026 figures. The company recorded an acceleration in organic revenue growth to 4.7% in the second quarter - the fastest pace seen in two years - alongside a 17.1% increase in adjusted net profit.
Results in detail
On a headline basis, Q2 reported revenue was 606 million, up 2.2% year-on-year. Management noted that the headline number was affected by approximately 3.5% of structural headwinds related to the Fit4Growth program, which includes the divestiture of the UK business and the exit from US managed care contracts. After accounting for those items, underlying momentum was substantially stronger.
Profitability also improved. Adjusted EBITDA for Q2 reached 156.2 million, a 6.1% increase, and the adjusted EBITDA margin expanded by 90 basis points to 25.8%. Cash generation strengthened materially in H1, with adjusted free cash flow rising 70% to 68 million.
Management commentary and guidance
Chief Executive Enrico Vita characterised the quarter as "risultati eccellenti, con la pi9 elevata crescita organica degli ultimi due anni, una performance superiore al mercato in tutte le aree geografiche" - excellent results with the highest organic growth in two years and above-market performance across all geographies. Management also confirmed its full-year guidance, reiterating expectations for organic growth above 3%.
Market reaction and context
The stronger-than-expected results and the decision to confirm guidance gave investors a clear reason to re-price the stock. The announcement, which came after the prior session's close, catalysed a move that pushed the share price well above its recent trading range, though it remained beneath the 52-week high of 16.045.
The rally occurred against a supportive backdrop in Italian equities, with the FTSE MIB trading higher on the day amid a wave of solid reported earnings from domestic blue-chips. Global risk appetite was also constructive, with US indices in positive territory, and there were no major sector-specific announcements from peers in hearing care or medical devices to explain the move. That suggests Amplifons own fundamentals were the primary driver.
Why the stock moved
Investors reacted to a combination of factors: accelerating organic top-line momentum, margin expansion, stronger cash conversion, confirmation of full-year guidance, and an encouraging start to the third quarter. Together, those elements provided the market with a substantive basis to lift the valuation, prompting the significant intraday gain.
Outlook and positioning
With management maintaining guidance and highlighting above-market performance across geographies, the company has signalled continuity in its strategic direction despite the structural adjustments from Fit4Growth. The market response indicates renewed investor confidence in the company's near-term trajectory, while the share price remains under its 52-week peak.
Note: All numerical figures, quotes and corporate actions referenced here are as reported by the company in its Q2 and H1 2026 disclosure.